Bodewes ILA, et al. - Herein, the experts aimed to evaluate the association between systemic interferon (IFN) type I (IFN-I) and II (IFN-II) activity and disease manifestations in primary Sjogren’s syndrome (pSS). Results demonstrated a relationship between the systemic IFN activation and higher activity only in the EULAR SS Disease Activity Index (ESSDAI) biological domain but not in other domains or the total score. It was determined that ESSDAI biological domain score could serve as a more sensitive endpoint for trials targeting either IFN pathway.